Tapentadol for acute and chronic pain

被引:2
作者
Sloan, Paul [1 ]
机构
[1] Univ Kentucky, Med Ctr, Dept Anesthesiol, Lexington, KY 40536 USA
关键词
DOUBLE-BLIND; NEUROPATHIC PAIN; PHASE-III; PLACEBO; HYDROCHLORIDE; EFFICACY;
D O I
10.1517/14656566.2010.495870
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:1783 / 1785
页数:3
相关论文
共 15 条
[1]   Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain [J].
Chou, Roger ;
Fanciullo, Gilbert J. ;
Fine, Perry G. ;
Adler, Jeremy A. ;
Ballantyne, Jane C. ;
Davies, Pamela ;
Donovan, Marilee I. ;
Fishbain, David A. ;
Foley, Kathy M. ;
Fudin, Jeffrey ;
Gilson, Aaron M. ;
Kelter, Alexander ;
Mauskop, Alexander ;
O'Connor, Patrick G. ;
Passik, Steven D. ;
Pasternak, Gavril W. ;
Portenoy, Russell K. ;
Rich, Ben A. ;
Roberts, Richard G. ;
Todd, Knox H. ;
Miaskowski, Christine .
JOURNAL OF PAIN, 2009, 10 (02) :113-130
[2]   Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain [J].
Christoph, Thomas ;
De Vry, Jean ;
Tzschentke, Thomas M. .
NEUROSCIENCE LETTERS, 2010, 470 (02) :91-94
[3]  
Daniels SE, 2009, CURR MED RES OPIN, V25, P765, DOI [10.1185/03007990902728183, 10.1185/03007990902728183 ]
[4]  
Etropolski M, 2009, NEUROLOGY, V72, pA217
[5]  
Hale M, 2009, CURR MED RES OPIN, V25, P1095, DOI [10.1185/03007990902816970, 10.1185/03007990902816970 ]
[6]   Tapentadol immediate release for the relief of moderate-to-severe acute pain [J].
Hartrick, Craig T. .
EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (16) :2687-2696
[7]   Single Dose Analgesic Efficacy of Tapentadol in Postsurgical Dental Pain: The Results of a Randomized, Double-Blind, Placebo-Controlled Study [J].
Kleinert, Regina ;
Lange, Claudia ;
Steup, Achim ;
Black, Peter ;
Goldberg, Jutta ;
Desjardins, Paul .
ANESTHESIA AND ANALGESIA, 2008, 107 (06) :2048-2055
[8]  
Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x
[9]  
Sloan Paul, 2006, J Opioid Manag, V2, P295
[10]  
Sloan Paul, 2006, Expert Opin Drug Deliv, V3, P489, DOI 10.1517/17425247.3.4.489